Among cancer patients who developed cardiotoxicity after treatment with immune checkpoint inhibitor (ICI) therapy, those treated with abatacept (Orencia), ruxolitinib, and/or mechanical ventilation as needed had a significantly ...
Feb 23, 2023
0
7
Immunotherapy after surgery increased bladder cancer patients' chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at ...
Feb 17, 2023
0
20
For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and ...
Feb 10, 2023
0
2
After six years of painful injections, Stephanie Walker has had enough.
Feb 8, 2023
0
4
New results from the FinnGen research consortium demonstrate the undeniable benefits of Finnish health research environment for genomic research. Among the wealth of novel genetic discoveries are previously unknown genetic ...
Jan 18, 2023
0
27
A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might ...
Jan 9, 2023
0
58
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated ...
Dec 7, 2022
0
4
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
9
Patients with advanced lung cancer had a better chance at survival when their treatment combined chemotherapy with a drug designed to turn the immune system against cancer, according to two studies released Sunday at a conference ...
Sep 12, 2022
0
9
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
16
